- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00126685
Vaccine Therapy in Treating Patients With Stage IV Melanoma
Vaccination of Stage IV Cutaneous Melanoma Patients With Mature, Autologous Monocyte-Derived Dendritic Cells Transfected With Unselected Autologous Amplified Tumor-RNA
RATIONALE: Vaccines made from a person's tumor cells and white blood cells may help the body build an effective immune response to kill tumor cells.
PURPOSE: This phase I/II trial is studying the side effects of vaccine therapy and to see how well it works in treating patients with stage IV melanoma.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
OBJECTIVES:
- Determine the safety and tolerability of vaccine therapy comprising autologous dendritic cells (DC) transfected with autologous polymerase chain reaction-amplified tumor RNA in patients with stage IV cutaneous melanoma.
- Determine whether tumor RNA- or tumor antigen-specific T-cell responses are induced in patients treated with this vaccine.
- Determine whether there are major differences in the immunogenicity of DC transfected at immature stage or at mature stage in patients treated with this vaccine.
- Determine objective tumor response in patients treated with this vaccine.
- Determine time to disease progression and progression-free interval in patients treated with this vaccine.
- Determine overall survival of patients treated with this vaccine.
OUTLINE: This is an open-label, nonrandomized study. Patients are sequentially assigned to receive dendritic cells (DC) transfected at either immature or mature stage.
Approximately 2-3 weeks before leukapheresis, patients undergo surgical excision or biopsy of the tumor to obtain tumor tissue for RNA isolation. RNA is amplified from the tumor sample by polymerase chain reaction (PCR). Patients then undergo leukapheresis to harvest peripheral blood mononuclear cells for the production of DC on day -14 . DC at immature or mature stage are transfected with autologous PCR-amplified tumor RNA to produce the vaccine. Patients receive vaccine intradermally (ID) on days 1, 15, 29, 43, 57, and between days 71-74 in the absence of disease progression or unacceptable toxicity. Patients undergo evaluation between days 71-74. Patients with responding or stable disease or minor disease progression receive booster vaccine ID on days 99, 127, between days 162-164, on day 205, between days 253-255, 351-354, 442-444, 533-535, 624-626, and 715-718 in the absence of disease progression or unacceptable toxicity. Patients also undergo additional leukapheresis between days 71-74, 351-354, and 715-718. Patients with responding or stable disease may continue to undergo leukapheresis and receive booster vaccine ID every 12-24 weeks off study.
After completion of study treatment, patients are followed periodically for up to 10 years.
PROJECTED ACCRUAL: A total of 8-30 patients will be accrued for this study within 6-12 months.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Erlangen, Germany, D-91052
- Dermatologische Klinik mit Poliklinik - Universitaetsklinikum Erlangen
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
DISEASE CHARACTERISTICS:
Histologically confirmed cutaneous melanoma*
- Stage IV disease (i.e., distant metastasis)
- Not curable by surgical resection
- NOTE: *Metastatic melanoma with an unknown primary tumor allowed provided ocular melanoma can be definitely excluded and origin from the skin is likely
Unidimensionally or bidimensionally measurable disease by physical examination and/or noninvasive radiological procedures
- At least 1 measurable metastasis that has not been previously excised or biopsied
- Failed ≥ 1 standard chemotherapy or chemoimmunotherapy regimen (e.g., dacarbazine or cisplatin monotherapy)
- At least 1 metastatic lesion surgically accessible* for excision or biopsy to obtain tumor material for RNA isolation** NOTE: *Surgically accessible metastatic lesion not required provided properly processed tumor material or isolated tumor RNA is available from a metastasis excised or biopsied within the past 6 months
NOTE: **Major surgery not allowed for the acquisition of metastatic material solely for RNA isolation
No active CNS metastases by CT scan or MRI
- Previously treated CNS metastases (e.g., by excision of a single metastasis, gamma knife radiosurgery, or stereotactic radiotherapy) allowed provided there is no evidence of active CNS metastasis by CT scan or MRI
PATIENT CHARACTERISTICS:
Age
- Over 18
Performance status
- Karnofsky 60-100%
Life expectancy
- At least 4 months
Hematopoietic
- WBC > 2,500/mm^3
- Neutrophil count > 1,000/mm^3
- Lymphocyte count > 700/mm^3
- Platelet count > 75,000/mm^3
- Hemoglobin > 9 g/dL
- No bleeding disorders
Hepatic
- Bilirubin < 2.0 mg/dL
- Hepatitis B surface antigen negative
- Hepatitis C antibody negative
Renal
- Creatinine < 2.5 mg/dL
Cardiovascular
- No clinically significant heart disease
Pulmonary
- No respiratory disease
Immunologic
- HIV-1 or -2 negative
- Human T-cell lymphotropic virus type I negative
- No known hypersensitivity to dimethylsulfoxide
- No immunodeficiency disease
- No active systemic infection
No active autoimmune disease (except vitiligo), including any of the following:
- Lupus erythematosus
- Scleroderma
- Rheumatoid arthritis (i.e., rheumatoid factor-positive arthritis with current or recent flare)
- Ankylosing spondylitis
- Autoimmune thyroiditis or uveitis
- Autoimmune hemolytic anemia
- Immune thrombocytopenic purpura
- Multiple sclerosis
- Inflammatory bowel disease
Other
- Not pregnant or nursing
- Negative pregnancy test
- Fertile female patients must use effective contraception during and for ≥ 4 weeks after completion of study treatment
- Willing to undergo excision or biopsy of metastasis
- Willing to be hospitalized for ≥ 24 hours after each vaccination
- Medical condition stable
- No contraindication to leukapheresis
- No organic brain syndrome
- No significant psychiatric abnormality that would preclude study participation
- No other active malignancy within the past 5 years except nonmelanoma skin cancer or carcinoma in situ of the cervix
- No other major serious illness
PRIOR CONCURRENT THERAPY:
Biologic therapy
- See Disease Characteristics
- More than 4 weeks since prior systemic immunotherapy
- No systemic immunotherapy during and for 2 weeks after completion of study treatment
Chemotherapy
- See Disease Characteristics
- More than 4 weeks since prior systemic chemotherapy
- No systemic chemotherapy during and for 2 weeks after completion of study treatment
Endocrine therapy
- No systemic corticosteroids, including steroid-containing inhalers or chronic use of topical steroids over large areas of the body (if systemic effects are likely or obvious) during and for 2 weeks after completion of study treatment
Radiotherapy
- See Disease Characteristics
- More than 2 weeks since prior radiotherapy
- No prior radiotherapy to the spleen
- Concurrent palliative radiotherapy to selected metastases for pain or local complications (e.g., compression) allowed
Surgery
- See Disease Characteristics
- Recovered from prior surgery
- No prior splenectomy
- No prior organ allograft
- Concurrent palliative surgery to selected metastases for pain or local complications (e.g., compression) allowed
Other
- Concurrent palliative hyperthermic therapy to selected metastases for pain or local complications (e.g., compression) allowed
- No concurrent participation in any other clinical trial
- No other systemic immunosuppressive agents (e.g., azathioprine or cyclosporine) during and for 2 weeks after completion of study treatment
- No other investigational drugs or paramedical substances during and for 2 weeks after completion of study treatment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Masking: NONE
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Overall survival
|
Time to disease progression
|
Safety
|
Objective tumor response
|
Progression-free interval
|
Immunogenicity
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CDR0000435933
- ERLANGEN-DERMA-ER-DC-07
- EU-20513
- ARGOS-ERLANGEN-DERMA-DC-07
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Melanoma (Skin)
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); University of VirginiaCompletedStage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage III Skin Melanoma | Stage IIA Skin Melanoma | Stage IIB Skin Melanoma | Stage IIC Skin Melanoma | Stage IIIA Skin Melanoma | Stage IA Skin Melanoma | Stage IB Skin Melanoma | Stage 0 Skin Melanoma | Stage I Skin Melanoma | Stage II Skin MelanomaUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)CompletedStage IV Skin Melanoma | Recurrent Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage IIA Skin Melanoma | Stage IIB Skin Melanoma | Stage IIC Skin Melanoma | Stage IIIA Skin Melanoma | Stage IA Skin Melanoma | Stage IB Skin MelanomaUnited States
-
National Cancer Institute (NCI)CompletedStage IV Skin Melanoma | Recurrent Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage IIA Skin Melanoma | Stage IIB Skin Melanoma | Stage IIC Skin Melanoma | Stage IIIA Skin Melanoma | Stage IA Skin Melanoma | Stage IB Skin MelanomaUnited States
-
William CarsonSchering-PloughCompletedStage IV Skin Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage IIA Skin Melanoma | Stage IIB Skin Melanoma | Stage IIC Skin Melanoma | Stage IIIA Skin Melanoma | Stage IA Skin Melanoma | Stage IB Skin MelanomaUnited States
-
Roswell Park Cancer InstituteCompletedStage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage IIA Skin Melanoma | Stage IIB Skin Melanoma | Stage IIC Skin Melanoma | Stage IIIA Skin Melanoma | Stage IB Skin MelanomaUnited States
-
Emory UniversityGenentech, Inc.Active, not recruitingStage IV Skin Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Unresectable Melanoma | Stage III Melanoma | Stage IIIA Skin Melanoma | Cutaneous Melanoma, Stage III | Cutaneous Melanoma, Stage IVUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedStage IV Skin Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage IIA Skin Melanoma | Stage IIB Skin Melanoma | Stage IIC Skin Melanoma | Stage IIIA Skin MelanomaUnited States
-
National Cancer Institute (NCI)CompletedStage IV Skin Melanoma | Recurrent Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Mucosal Melanoma | Stage IIIA Skin MelanomaUnited States, Australia
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI); Incyte Corporation; University of VirginiaCompletedStage IV Skin Melanoma | Recurrent Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Mucosal Melanoma | Stage IV Uveal Melanoma | Stage IIIA Skin Melanoma | Stage IIIA Uveal Melanoma | Stage IIIB Uveal Melanoma | Stage IIIC Uveal Melanoma | Recurrent Uveal MelanomaUnited States
-
National Cancer Institute (NCI)CompletedStage IV Skin Melanoma | Recurrent Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage IIIA Skin MelanomaUnited States
Clinical Trials on therapeutic autologous dendritic cells
-
Jonsson Comprehensive Cancer CenterKite, A Gilead CompanyCompletedClear Cell Renal Cell Carcinoma | Stage IV Renal Cell Cancer | Recurrent Renal Cell CancerUnited States
-
Jonsson Comprehensive Cancer CenterNational Institutes of Health (NIH)CompletedBrain and Central Nervous System TumorsUnited States
-
Jonsson Comprehensive Cancer CenterCompletedBrain and Central Nervous System TumorsUnited States
-
Duke UniversityNational Cancer Institute (NCI)Terminated
-
Lisata Therapeutics, Inc.CompletedMelanoma (Skin)United States
-
Institut Paoli-CalmettesCompleted
-
Dana-Farber Cancer InstituteNational Cancer Institute (NCI)UnknownMelanoma (Skin)United States
-
Gary Archer Ph.D.National Cancer Institute (NCI)CompletedMalignant Neoplasms of BrainUnited States
-
Dartmouth-Hitchcock Medical CenterNational Cancer Institute (NCI)CompletedMelanoma (Skin)United States
-
Lisata Therapeutics, Inc.Terminated